New world and old world Leishmania infections: A 447 Practical Review, Dermatol Clin, vol.33, pp.579-593, 2015. ,
Antimony transport mechanisms in resistant 449 leishmania parasites, Biophys Rev, vol.6, pp.119-132, 2014. ,
Visceral leishmaniasis: Revisiting current treatments and approaches for future 451 discoveries, Acta Trop, vol.155, pp.113-123, 2016. ,
A novel mechanism for an old drug: amphotericin B in 453 the treatment of visceral leishmaniasis, Biochem Biophys Res Commun, vol.416, pp.7-12, 2011. ,
, , p.455
How can micelle systems be rebuilt by a heating process, Int J 456 Nanomedicine, vol.7, pp.141-150, 2012. ,
,
Anti-leishmanial activity of a new formulation of amphotericin B, p.459, 2004. ,
, Med Int Health, vol.9, pp.981-990
Activity of a heat-induced 461 reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani, 1999. ,
, Antimicrob Agents Chemother, vol.43, pp.390-392
, , p.464, 2002.
, Amphotericin B in sterol-free and cholesterol-or ergosterol-containing supported, J, vol.83, pp.3245-3255
Heat-induced reformulation of amphotericin 468, 2003. ,
, B-deoxycholate favours drug uptake by the macrophage-like cell line J774, J Antimicrob 469 Chemother, vol.52, pp.904-910
In-vivo therapeutic 471 efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin 472 B obtained by mild heating, J Antimicrob Chemother, vol.42, pp.779-785, 1998. ,
Fluorescence of amphotericin B-deoxycholate 474 (fungizone) monomers and aggregates and the effect of heat-treatment, Langmuir, vol.23, p.8718, 2007. ,
Parenteral microemulsions: an overview, Int J Pharm, vol.477, pp.19-30, 2008. ,
Amphotericin B microemulsion reduces 480 toxicity and maintains the efficacy as an antifungal product, J Biomed Nanotechnol, vol.8, pp.290-481, 2012. ,
, , p.483
Development and characterization of a 484 microemulsion system containing Amphotericin B with potential ocular applications, Curr 485 Neuropharmacol, vol.14, pp.1-1, 2016. ,
Physico-chemical properties of the heat-487 induced 'superaggregates' of amphotericin B, Biophys Chem, vol.66, pp.1-12, 1997. ,
, , p.489
Synthesis and antikinetoplastid activities of 3-substituted quinolinones 490 derivatives, Eur J Med Chem, vol.52, pp.44-50, 2012. ,
Host resistance to the Khartoum strain of Leishmania donovani, Rice, vol.492, pp.80-96, 1958. ,
, , p.494
Mechanism of amphotericin B resistance in clinical isolates of 495, 2012. ,
, Antimicrob Agents Chemother, vol.56, pp.1031-1041
Microemulsion-based media as novel drug delivery systems, 2000. ,
, Adv Drug Deliv Rev, vol.45, pp.89-121
Formulation development of parenteral phospholipid-499 based microemulsion of etoposide, AAPS PharmSciTech, vol.11, pp.826-831, 2010. ,
, , 2014.
, Development of antileishmanial lipid nanocomplexes, Biochimie, vol.107, pp.143-153
Development of oil-in-water microemulsions 503 for the oral delivery of amphotericin B, Int J Pharm, vol.454, pp.641-648, 2013. ,
New lipid formulation 505 of amphotericin B: spectral and microscopic analysis, BBA Biomembranes, vol.1664, pp.172-181, 2004. ,
, , p.507
Self-association of Amphotericin B: Spontaneous formation of molecular 508 structures responsible for the toxic side effects of the antibiotic, J Phys Chem B, vol.118, pp.13821-509, 2014. ,
Amphotericin B-induced nephrotoxicity: a review, J Chemother, vol.511, pp.463-470, 2000. ,
, , p.513
Comparison of a high-throughput high-514 content intracellular Leishmania donovani assay with an axenic amastigote assay, Antimicrob 515 Agents Chemother, vol.57, pp.2913-2922, 2013. ,
, , p.517, 2011.
, Leishmania intracellular amastigotes: comparison to a promastigote screen and identification 518 of a host cell-specific hit, PLoS Negl Trop Dis, vol.5, p.1253
Heat-induced superaggregation of 520, 1997. ,
, amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index
, Antimicrob Agents Chemother, vol.41, pp.2345-2351
, , 2011.
, Icacina senegalensis (Icacinaceae), traditionally used for the treatment of malaria, inhibits in 524 vitro Plasmodium falciparum growth without host cell toxicity, Malar J, vol.10, p.85
Selection of the most promising 2-substituted quinoline as antileishmanial 527 candidate for clinical trials, Biomed Pharmacother, vol.62, pp.684-689, 2008. ,